Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 4:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 4,614 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genital Diseases, Male Clear all
Active, not recruiting Not applicable Interventional

The Use of Artificial Intelligence Generated Contours in Radiation Planning of the Prostate Brachytherapy

NCT06964412
View directory record Official record
Conditions
Prostate Cancer
Interventions
Artificial-intelligence (AI)
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Terminated Phase 1 Interventional

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

NCT05037500
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Decitabine and Cedazuridine, Enzalutamide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

NCT00059631
View directory record Official record
Conditions
Prostate Cancer
Interventions
Mitoxantrone (Novantrone), Bortezomib (PS-341)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00058253
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin, docetaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1Phase 2 Interventional

Study Evaluating the Safety and Tolerability of L-377202

NCT00987753
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer, Prostate Cancer
Interventions
L-377202
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 12, 2026, 4:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients

NCT02401867
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Sexually Transmitted Diseases
Interventions
Not listed
Lead sponsor
Fenway Community Health
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 12, 2026, 4:39 PM EDT
Terminated Not applicable Interventional Results available

Effect of Ejaculatory Abstinence on Semen Parameters in Male Factor Infertility Patients

NCT04206800
View directory record Official record
Conditions
Infertility, Male
Interventions
Ejaculatory abstinence less than 24 hours
Diagnostic Test
Lead sponsor
Boston IVF
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Not applicable Interventional

Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy

NCT02869412
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Computer-Assisted Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 12, 2026, 4:39 PM EDT
Terminated Phase 2 Interventional Results available

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

NCT03964337
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
Interventions
Cabozantinib, Radical Prostatectomy
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 12, 2026, 4:39 PM EDT
Completed No phase listed Observational

The AIM Study: Assessing the Impact of Margin Reduction

NCT00754000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Observation
Other
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Scottsdale, Arizona • Santa Monica, California • Cape Coral, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 12, 2026, 4:39 PM EDT
Completed No phase listed Observational

Familial Prostate Cancer

NCT00001377
View directory record Official record
Conditions
Neoplastic Syndromes, Hereditary, Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

NCT01317199
View directory record Official record
Conditions
Prostate Cancer
Interventions
Muscadine Plus Grape Skin Extract, Low-dose MPX, High-dose MPX, Placebo oral capsule
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Not applicable Interventional

Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study

NCT03931538
View directory record Official record
Conditions
Urinary Tract Infections, Prostatitis, Interstitial Cystitis
Interventions
Guidance 4.0 PCR test, Urine Culture
Diagnostic Test
Lead sponsor
Pathnostics
Industry
Eligibility
18 Years and older
Enrollment
2,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Cancer Disparities for American Indians in the Rural Intermountain West

NCT00380055
View directory record Official record
Conditions
Prostate Cancer, Colorectal Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions
Navigation Services, Cancer education
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
2
States / cities
Great Falls, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Phase 1 Interventional

Safety Study of MGA271 in Refractory Cancer

NCT01391143
View directory record Official record
Conditions
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions
MGA271
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 12, 2026, 4:39 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Perspectives About Online Information

NCT07631858
View directory record Official record
Conditions
Prostate Cancer
Interventions
Post (video) about prostate cancer, Post (text post) about prostate cancer, Survey
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Germ Cell Tumor and Testicular Tumor DNA Registry

NCT02099734
View directory record Official record
Conditions
Germ Cell Tumor, Testicular Tumor
Interventions
Questionnaires, sample of blood or saliva
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2028
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Withdrawn Phase 2 Interventional

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

NCT04585932
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Apalutamide, Degarelix, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 12, 2026, 4:39 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans

NCT07852949
View directory record Official record
Conditions
Head and Neck Cancer, Prostate Cancer
Interventions
Survey
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Recruiting Phase 3 Interventional

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443
View directory record Official record
Conditions
Metastatic Castration-resistant Prostatic Neoplasms
Interventions
Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401
Biological · Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
54
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Completed No phase listed Observational

Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data

NCT04897958
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Male only
Enrollment
14,417 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 12, 2026, 4:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Peer Genetic Study

NCT05011799
View directory record Official record
Conditions
Healthy Subject, Prostate Carcinoma
Interventions
Cancer Educational Materials, Questionnaire Administration, Educational Intervention
Behavioral · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
35 Years to 69 Years · Male only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 12, 2026, 4:39 PM EDT
Terminated Phase 2 Interventional

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

NCT01340599
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, questionnaire administration, therapeutic conventional surgery, high performance liquid chromatography, mass spectrometry
Dietary Supplement · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 12, 2026, 4:39 PM EDT